Anti-VEGF Treatment in Corneal Diseases.

CONCLUSION: The efficacy and safety of anti-VEGF agents support their adoption into the daily clinical practice for the management of CN.
PMID: 32189591 [PubMed - as supplied by publisher]

Source: Current Drug Targets - March 18, 2020 Category: Drugs & Pharmacology Authors: Giannaccare G, Pellegrini M, Bovone C, Spena R, Senni C, Scorcia V, Busin M Tags: Curr Drug Targets Source Type: research